IP Library Granted Patent US 10,759,843
Granted Patent B2
US 10,759,843 · App. 16/161,931 · Granted Sep 1, 2020

Method and pharmaceutical composition for use in the treatment of cancer

Inventors: Santos Susin (Paris, FR); Pierre Launay (Paris, FR); Philippe Karoyan (Paris, FR); Helene Merle-Beral (Paris, FR)
Assignee: Philippe Karoyan
C07K14/78A61K38/08C07K7/06A61K38/00A61K48/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,759,843
App. No.
16/161,931
Granted
Sep 1, 2020
Kind
B2
Abstract

The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Claims (10)

1. A method for treating cancer in an individual comprising administering to the individual a therapeutically effective amount of a peptide of the following formula (I), or a pharmaceutically acceptable salt thereof:

wherein the cancer is leukemia, breast cancer, colorectal cancer, pancreatic cancer or glioblastoma.

2. The method of claim 1 , wherein the cancer is acute lymphoblastic leukemia, B-chronic lymphocytic leukemia, hairy-cell leukemia, adult T-cell leukemia, prolymphocytic leukemia of T-cell type or myeloid leukemia.

3. The method of claim 1 , wherein the cancer is B-chronic lymphocyte leukemia (CCL).

4. The method of claim 1 , wherein the cancer is refractory chronic lymphocyte leukemia (CCL).

5. A method of destructing tumor cells, comprising contacting the tumor cells with an effective amount of a peptide of the following formula (I), or a pharmaceutically acceptable salt thereof:

6. A peptide of the following formula (I):

7. A pharmaceutical composition comprising the peptide of claim 6 , or a pharmaceutical acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7 , which is formulated for a topical, oral, intranasal, intraocular, intravenous, intramuscular or subcutaneous administration.

9. The pharmaceutical composition of claim 7 , which is in an injectable form.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2024
From: KAROYAN, PHILIPPE
To: PEPKON SAS
Reel/Frame 069249/0340 →
MERGER Recorded Mar 16, 2020
From: UNIVERSITE PIERRE ET MARIE CURIE UPMC
To: SORBONNE UNIVERSITÉ
Reel/Frame 052128/0380 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 26, 2018
From: FRENCH NATIONAL INSTITUTE OF HEALTH AND MEDICAL RESEARCH; SORBONNE UNIVERSITÉ; UNIVERSITE PARIS DIDEROT; UNIVERSITÉ PARIS DESCARTES; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
To: PHILIPPE KAROYAN
Reel/Frame 047854/0805 →
Priority Claims (1)
EP 12305636 · Jun 6, 2012 · regional
Continuity (4)
Continuation 15687692 · Aug 28, 2017
Continuation 14874657 · Oct 5, 2015
Continuation 14406091
Related Publication 20190135898A1 · May 9, 2019